
Tegaserod maleate
CAS No. 189188-57-6
Tegaserod maleate( SDZ-HTF 919 | Zelnorm )
Catalog No. M12965 CAS No. 189188-57-6
Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
10MG | 35 | In Stock |
![]() ![]() |
25MG | 65 | In Stock |
![]() ![]() |
50MG | 110 | In Stock |
![]() ![]() |
100MG | 188 | In Stock |
![]() ![]() |
200MG | 285 | In Stock |
![]() ![]() |
500MG | 482 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameTegaserod maleate
-
NoteResearch use only, not for human use.
-
Brief DescriptionTegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation.
-
DescriptionTegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome.
-
In VitroApoptosis Analysis Cell Line:A375, RPMI-7951 (RPMI), SH4, B16F10, MeWo and MEL-JUSO.Concentration:3, 5 μM Incubation Time:24, 48, 72 h Result:There was a significant time and dose-dependent increase in apoptosis in all cell lines.Western Blot Analysis Cell Line:RPMI, SH4 and B16F10 cells.Concentration:3, 5 μM Incubation Time:8 or 18?h Result:Decreased phosphorylation of the kinase directly upstream of S6, p70 S6 at Thr421/Ser424.
-
In VivoAnimal Model:C57BL/6?J mice were subcutaneously injected with B16F10 cellsDosage:5?mg/kg Administration:Administered intraperitoneally (i.p.) daily for five consecutive days Result:Treatment significantly decreased tumor growth and resulted in only slight decreases in weight following treatment.Animal Model:Female C57BLKS/J db/db mice Dosage:0.1, 0.5, 1.0, 2.0 mg/kg Administration:IP; 15 min prior to gastric loading Result:Produced a dramatic decrease in the fraction of the meal remaining in the stomach for doses as low as 0.1 mg/kg (0.1 mg/kg).Accelerated gastric emptying, with a reduction of nearly 80% in the fraction remaining at 30 min (P < 0.0001) (0.1 mg/kg).Induced a significant decrease in the gastric emptying rate as the amount of the meal remaining at 30 min was significantly greater (2.0 mg/kg).Resulted in inhibition of tegaserod-induced increased gastric emptying (0.1 mg/kg).
-
SynonymsSDZ-HTF 919 | Zelnorm
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptor5-HT| Sert (Sodium-dependent)
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number189188-57-6
-
Formula Weight417.46
-
Molecular FormulaC20H27N5O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 35mg/mL
-
SMILESCCCCCN=C(N)NN/C=C/1\C=NC2=C1C=C(C=C2)OC.C(=C\C(=O)O)\C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Beattie DT, et al. Br J Pharmacol. 2004 Nov;143(5):549-60.
molnova catalog



related products
-
Nafronyl oxalate
A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic.
-
CID-25014542
CID-25014542 is novel inhibitor of Raf kinases.
-
AVN-101 hydrochlorid...
AVN-101 is a very potent 5-HT7 receptor antagonist (Ki = 153 pM). AVN-101 also exhibits a rather high affinity toward histamine H1 (Ki = 0.58 nM) and adrenergic α2A, α2B, and α2C (Ki = 0.41-3.6 nM) receptors.